The follow-up of 360 patients with pulmonary tuberculosis after 2 months treatment with anti-tubercular agents in Iran

Kazerani, M. and Kazerani, M. and Ashrafzadeh, K. and Rahiman, S. and Mottaghy, M. and Samihi, A. A. (2018) The follow-up of 360 patients with pulmonary tuberculosis after 2 months treatment with anti-tubercular agents in Iran. Archives of Clinical Infectious Diseases, 13 (4).

[img] Text
The follow-up of 360 patients with pulmonary tuberculosis after 2 months treatment with anti-tubercular agents in Iran.pdf

Download (173kB)

Abstract

Background: Tuberculosis (TB) is a major global health problem. The goal is to end the global TB epidemic. TB treatment averted 49 million deaths globally from 2000 to 2015. If everyone with TB had a timely diagnosis and high-quality treatment, the TB case fatality rate would be lower in all countries. The main source of infection is untreated smear positive pulmonary TB; the next step should be the examination of the sputum for Mycobacterium sp. Bacteriologic evaluation through culture and /smear microscopy is essential to monitor the response to treatment. Monitoring acid-fast bacilli (AFB) smear should be undertaken at 2, 5, and 6 months. The currently recommended treatment for the new cases of drug-susceptible TB is a 6-month regimen of 4 first-line drugs: isoniazid (INH), rifampin (RIF), ethambutol (ETM), and pyrazinamide (PZA). Treatment success rates of at least 85 for new cases of drug-susceptible TB are regularly reported to the world health organization (WHO) by its 194 member states. The global TB drug facility supplies a complete 6-month course for about US 40 per person. Objectives: The current study aimed at evaluating the effectiveness of directly observed treatment short course (DOTS), AFB-negative/AFB-positive sputum after a 2-month treatment with the 4 first-line drugs. Methods: A total of 700 patients with tuberculosis referred to Sanabad Health Center of Mashhad, Iran from March 2005 to March 2008 were retrospectively studied. Then, 360 new smear-positive pulmonary TB were chosen. After 2 months of treatment with 4 anti-tubercular agents, age, gender, nationality, and AFB-negative, AFB-positive of sputum smear were recorded in 2 groups. Results: Females were infected more than males. There were treatment success rates of at least 86.4 for new cases of drug-susceptible TB. Age, gender, and nationality were not related to the changes in sputum (negative-positive). Conclusions: DOTS were effective in the current study. In low-and middle-income countries, in patients with TB cavity, diabetes, malnutrition, immune disorder, and cigarettes smoking, the sputum smear and culture testing on the days 15 and 30 of treatment until the completion of the treatment should be done. © 2017, Archives of Clinical Infectious Diseases.

Item Type: Article
Additional Information: Export Date: 16 February 2020 Correspondence Address: Kazerani, M.Hejrat Street 6c, Iran; email: kazerani1617@mshdiau.ac.ir
Uncontrolled Keywords: Anti-tubercular agents Ethambutol Isoniazid Mycobacterium tuberculosis Pulmonary tuberculosis Pyrazinamide Rifampin Tuberculosis ethambutol plus isoniazid plus pyrazinamide plus rifampicin acid fast bacterium adolescent adult age distribution aged antibiotic sensitivity Article autoimmune disease cigarette smoking controlled study cross-sectional study diabetes mellitus drug efficacy drug response ethnicity female follow up health center human infection control Iran low income country lung cavity lung tuberculosis major clinical study male malnutrition middle income country nonhuman retrospective study sex difference short course therapy sputum culture sputum smear
Subjects: WF Respiratory System
QV pharmacology
Divisions: Mashhad University of Medical Sciences
Depositing User: lib2 lib2 lib2
Date Deposited: 11 May 2020 08:59
Last Modified: 11 May 2020 08:59
URI: http://eprints.mums.ac.ir/id/eprint/17360

Actions (login required)

View Item View Item